Marseille

• A Phase 1/2 Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors Ended
  2022-503060-33-00 4 Advanced or Metastatic Solid Tumor Malignancies
• A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metast … Ended
  2022-503080-15-00 1 Cancer
• PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carc … Ended
  2023-503807-27-00 4 Biliary tract carcinoma
• Study of BMS-986466 with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Solid Tumors Ended
  2023-505070-15-00 9 Oncology, NSCLC and CRC
• A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edem … Ended
  2023-507207-66-00 5 Diabetic Macular Edema (DME)
• A trial to find out if vidutolimod together with cemiplimab is safe and if it works in adult participants with advanced cancer or metastatic … Ended
  2023-507344-36-01 4 Advanced or Metastatic Cancer Merkel Cell Carcinoma (MCC) Cutaneous Sq
• ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in pati … Ended
  2023-509227-41-00 4 Low risk of disease recurrence, defined by the following criteria: - A
• A Clinical Study of Mitapivat in Patients with Sickle Cell Disease and Kidney Disease Ended
  2023-510289-28-00 4 Sickle Cell Disease (SCD) and Nephropathy
• Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended
  2023-510361-97-00 5 Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodys
• An Open-Label, Multicenter, Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1604 in Adults with Advanced Melanoma Ended
  2024-511949-19-00 1 Metastatic Melanoma
• Effect of Copper CU64 PSMA I&T scanning to detect potential disease spread to lymph nodes in men with newly diagnosed Prostate Cancer Ended
  2024-512754-16-01 5 Prostate cancer
• Open-label non-randomized multicentric phase 2 study evaluating the combination of bemarituzumab + FLOT chemotherapy in perioperative settin … Ended
  2024-514078-29-00 4 gastric and gastro-oesophageal junction adenocarcinomas
• A clinical study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with metastatic nons … Ended
  2024-515393-27-00 4 Nonsquamous non-small cell lung cancer
• Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanc … Ended
  2024-515533-15-00 4 Locally advanced cervical cancer
• Trial assessing the efficacy of suraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer Ended
  2024-516558-24-00 4 Pancreatic (PAAD)
• Trail aiming to assess the safety and clinical activity of bemarituzumab + bevacizumab in advanced/metastatic gynecological cancer overexpre … Ended
  2024-516724-33-00 9 Advanced/metastatic gynecological cancer overexpressing FGFR2b
• LONG-TERM INTERVENTIONAL FOLLOW-UP STUDY UP TO 4 YEARS OF AGE OF CHILDREN WITH PRADER-WILLI SYNDROME INCLUDED IN THE OTBB3 CLINICAL TRIAL AN … Ended
  2024-517925-25-00 4 prader-willi syndrome
• PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) … Ended
  2024-519258-35-00 4 stomach cancer
• A trial to find out how well CVHNLC works at different dose levels and how safe it is in combination with pembrolizumab in patients with lun … Ended
  2024-519651-28-00 1 metastatic squamous non-small cell lung cancer
• A Study of Valemetostat Tosylate Plus Pembrolizumab versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations Ended
  2024-519671-26-00 9 Advanced or Metastatic Non-Small Cell Lung Cancer
• A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced melanoma Ended
  2025-522054-40-00 4 Previously treated advanced melanoma

Showing 1,465–1,485 of 1,485 trials